Cargando…

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?

Detalles Bibliográficos
Autores principales:	Bernardi, Marco, Spadafora, Luigi, Galli, Mattia, Biondi-Zoccai, Giuseppe, Sabouret, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074288/ https://www.ncbi.nlm.nih.gov/pubmed/37034516 http://dx.doi.org/10.5114/aoms/160006

Ejemplares similares

Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies
por: Spadafora, Luigi, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Out-of-hospital cardiac arrest: predict and then protect!
por: Spadafora, Luigi, et al.
Publicado: (2023)

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

Coronary artery bypass grafting added to surgical aortic valve replacement in octogenarians
por: Spadafora, Luigi, et al.
Publicado: (2022)

Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence
por: Cacciatore, Stefano, et al.
Publicado: (2023)

Proton-pump inhibitors should be strictly prescribed in clinic
por: Yang, Xuesong, et al.
Publicado: (2022)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

New approaches to reduce recurrent PCI: to angioplasty and beyond!
por: Sabouret, Pierre, et al.
Publicado: (2023)

Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
por: Yousaf, Zohaib, et al.
Publicado: (2021)

SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites
por: Gao, Yuan, et al.
Publicado: (2021)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
por: De Pascalis, Antonio, et al.
Publicado: (2020)

Prescribing gliptins: Enthusiasm should be coupled with caution
por: Garg, M. K., et al.
Publicado: (2012)

The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients
por: Soni, Shubham, et al.
Publicado: (2020)

Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021)

When early discharge after percutaneous coronary intervention is much too early
por: Siudak, Zbigniew, et al.
Publicado: (2022)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions
por: Perone, Francesco, et al.
Publicado: (2023)

Euglycaemic ketoacidosis after abdominal surgery: Implications of SGLT2 inhibitors for anaesthesiologists – A case study
por: Kartha, Anandajith P., et al.
Publicado: (2023)

Reply to work from home culture and acute cardiovascular events: A bidirectional conundrum yet to be resolved!
por: Versaci, Francesco, et al.
Publicado: (2021)

SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
por: Sung, Jasper, et al.
Publicado: (2018)

SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?
por: Chatterjee, Subhankar
Publicado: (2020)

Prescribing COVID-19 treatments: what we should never forget
por: Tunesi, S., et al.
Publicado: (2020)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

In Reply to ‘Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
por: Neuwirt, Hannes, et al.
Publicado: (2020)

Should all coronary artery perforations be treated immediately?
por: Tatli, Ersan, et al.
Publicado: (2016)

Prescribing Aspirin for Preeclampsia Prevention in Pregnant Women During COVID-19: Should or Shouldn’t?
por: Eslamian, Laleh, et al.
Publicado: (2021)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Should all COVID-19 patients be approached in the same way?
por: Fernandes, Caio Julio Cesar dos Santos
Publicado: (2020)

Drucebo effect – the challenge we should all definitely face!
por: Banach, Maciej, et al.
Publicado: (2021)

SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoring
por: Kirschbaum, Klara, et al.
Publicado: (2021)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
por: Hackett, Geoffrey
Publicado: (2020)

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na(+)?
por: Trum, Maximilian, et al.
Publicado: (2021)

Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies
por: Iervolino, Adelaide, et al.
Publicado: (2022)

Air pollution and cardiovascular risk: is it time to change guidelines?
por: Bernardi, Marco, et al.
Publicado: (2022)

Response to “Drucebo effect – the challenge we should all definitely face!”
por: Howard, James Philip, et al.
Publicado: (2021)

Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper
por: Sabouret, Pierre, et al.
Publicado: (2022)

What All We Should Know About Masks in COVID-19 Pandemic
por: Agrawal, Himanshu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3p0fd2pau86au4v17b9c76rni